Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after showing products at Booth 1905 and hosting a November 11 workshop. No thunderbolt, but this is exactly where molecular diagnostics earns or loses credibility. A glossy claim means very little if an assay stalls on difficult RNA, blood, or real-world inhibitors.
Closed-Loop Design Gets a Real Test
Fapon’s central pitch is an AI-driven enzyme engineering process paired with high-throughput wet-lab screening. Candidates are designed, tested, and fed back into the model for another selection round. That loop is more useful than tossing “AI” onto a brochure and calling it innovation, although the proof still lives in independent, application-specific performance. According to the company’s workshop presentation, after two rounds of design and selection, its AI-engineered MMLV reverse transcriptases generated cDNA from RNA templates up to 9 kb at 60°C. That is a concrete technical result, not a vague promise.
The other item worth watching was TeloScript II, a reverse transcriptase aimed at full-length cDNA synthesis for long-read sequencing, including templates with difficult secondary structures. An invited speaker discussed a full-length transcriptomics study in which long-read sequencing helped resolve complex fusion genes and transcript isoforms. That matters because RNA biology is not always neat, and fragmented or incomplete reads can leave important distinctions buried. Still, a workshop discussion is not the same thing as broad clinical validation. Sensible observers should keep those categories separate.
Speed Claims Need Their Sample Context
ProPrime II Taq DNA Polymerase was the loudest practical performance story. Fapon says its antibody-based hot-start formulation fully releases after 10 seconds of heat activation and can complete 41 cycles of quadruplex qPCR in under 20 minutes. If that holds up across customer assay designs, it addresses a genuine pain point for multiplex panels and near-patient testing: labs want speed, but not at the expense of signal quality or tolerance for unpleasant sample matrices.
Fapon also says ProPrime II has been evaluated for direct amplification in 5% whole blood and with nine common PCR inhibitors. That language deserves to be read carefully. “Evaluated” is not the same as universally proven, and every assay developer knows a result can shift with targets, extraction choices, panel complexity, and instrument settings. But the direction is sound. In diagnostics, inhibitor resistance is not some side feature; it can be the difference between a streamlined workflow and another expensive workaround.
- ProPrime II targets rapid, multiplexed qPCR and challenging samples.
- MeloScript III WS is built for one-step RT-qPCR and retains reverse-transcription performance after 10 minutes at 52–64°C.
- Its glycerol-free, lyophilization-ready format fits the practical demands of dry reagent and near-patient formats.
RNA Workflows Are Where the Details Bite
Fapon did not lean on a one-enzyme-fits-all story, thankfully. PreciAmp HS RT is positioned for RT-LAMP and is described as maintaining performance in the presence of ethanol, viral preservation solutions, and sample release agents. VeloScript I, meanwhile, is geared toward long-read sequencing and NGS workflows, with claimed full-length cDNA synthesis up to 15 kb from RNA inputs ranging from 10 pg to 10 ?g. Those are very different jobs, and treating them as such is more credible than pretending one chemistry solves the whole bench.
Sample Preparation Fills Out the Offering
The broader workflow angle included the NK081 Poly(A) mRNA Magnetic Isolation Module, which Fapon says removes at least 95% of rRNA in under 40 minutes, plus the NextGen Universal FS DNA Library Prep Kit, designed to finish library preparation in under an hour. These tools matter because enzyme performance is only one piece of the chain. A clever reverse transcriptase cannot rescue a workflow that loses time or consistency upstream.
A Useful Showing, Not a Verdict
Fapon says it serves more than 2,500 partners across over 70 countries and regions, and AMP gave it a chance to speak with molecular pathologists, assay developers, and IVD manufacturers. For anyone watching the diagnostics-tools sector, that commercial reach is worth noting, but the real test comes afterward: evaluations, repeat orders, integration into customer assays, and performance outside a conference hall. The company’s enzyme claims are specific enough to merit attention. The next thing that counts is whether those claimed gains remain intact when somebody else’s lab, sample mix, and workflow take over.